Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EBT (2016 - 2025)

Historic EBT for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $340.7 million.

  • Dexcom's EBT rose 6123.99% to $340.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 5351.2%. This contributed to the annual value of $1.1 billion for FY2025, which is 5351.2% up from last year.
  • As of Q4 2025, Dexcom's EBT stood at $340.7 million, which was up 6123.99% from $352.3 million recorded in Q3 2025.
  • Dexcom's EBT's 5-year high stood at $352.3 million during Q3 2025, with a 5-year trough of $6.4 million in Q4 2021.
  • Its 5-year average for EBT is $157.8 million, with a median of $150.2 million in 2022.
  • As far as peak fluctuations go, Dexcom's EBT tumbled by 9584.95% in 2021, and later skyrocketed by 198125.0% in 2022.
  • Dexcom's EBT (Quarter) stood at $6.4 million in 2021, then surged by 1981.25% to $133.2 million in 2022, then skyrocketed by 84.83% to $246.2 million in 2023, then fell by 14.18% to $211.3 million in 2024, then soared by 61.24% to $340.7 million in 2025.
  • Its EBT stands at $340.7 million for Q4 2025, versus $352.3 million for Q3 2025 and $241.1 million for Q2 2025.